Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1(Currently amended). A tumor cell transfected with a DNA coding for at least one MHC class II ligand selected from the group consisting of [[CD4,]] LAG-3, and ~~derivatives~~ a derivative thereof that maintains the ability to bind the MHC Class II molecules which bind LAG-3.

Claim 2 (Cancelled).

3(Currently amended). A process for preparing the tumor cell of claim 1, comprising:

removing tumor cells from a patient;

transfecting a tumor cell with a DNA coding for at least one MHC class II ligand selected from the group consisting of [[CD4,]] LAG-3, and ~~derivatives~~ a derivative thereof that maintains the ability to bind the MHC Class II molecules which bind LAG-3; and

recovering the transfected tumor cell.

Claims 4-6 (Cancelled).

7(Currently amended). A pharmaceutical composition for treating pathological conditions involving an antigen specific

immune response, comprising a pharmaceutically acceptable vehicle and cells transfected with DNA coding for ~~at least one~~ MHC class II ligand ~~selected from the group consisting of CD4 and~~ LAG-3 and expressing LAG-3 ~~said at least one MHC class II ligand~~.

Claim 8 (Cancelled).

9(Previously presented). A method for treating a pathological condition involving antigen specific T-cell mediated immune response, comprising administering the pharmaceutical composition of claim 7 to a subject in need thereof.

10(New). A tumor cell according to claim 1, wherein said LAG-3 derivative that maintains the ability to bind the MHC Class II molecules which bind LAG-3 is a mutant or a soluble fragment of LAG-3 selected from the group consisting of a soluble fragment of LAG-3 consisting of at least one of the four immunoglobulin extracellular domains D1-D4, a fragment of LAG-3 consisting of the extracellular domains D1 and D2, a fragment of LAG-3 consisting of the four immunoglobulin extracellular domains D1-D4, a mutant form of a soluble LAG-3 comprising the extracellular domains D1 and D2, said mutant defined by one or more amino acid substitutions selected from the group consisting of:

Arg at residue position 73 substituted with Glu;

Arg at residue position 75 substituted with Ala;

Arg at residue position 75 substituted with Glu; and

Arg at residue position 76 substituted with Glu.

11(New). A process according to claim 3, wherein said LAG-3 derivative that maintains the ability to bind the MHC Class II molecules which bind LAG-3 is a mutant or a soluble fragment of LAG-3 selected from the group consisting of a soluble fragment of LAG-3 consisting of at least one of the four immunoglobulin extracellular domains D1-D4, a fragment of LAG-3 consisting of the extracellular domains D1 and D2, a fragment of LAG-3 consisting of the four immunoglobulin extracellular domains D1-D4, a mutant form of a soluble LAG-3 comprising the extracellular domains D1 and D2, said mutant defined by one or more amino acid substitutions selected from the group consisting of:

Arg at residue position 73 substituted with Glu;

Arg at residue position 75 substituted with Ala;

Arg at residue position 75 substituted with Glu; and

Arg at residue position 76 substituted with Glu.

12(New). A pharmaceutical composition according to claim 7, wherein said cells are tumor cells.